이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

국소성 또는 소수전이성 전립선암이 있는 흑인 또는 아프리카계 미국인 환자의 생존자 치료에 대한 이해와 접근성을 향상시키기 위한 맞춤형 생존자 치료 계획

2026년 9월 29일 업데이트: Viraj Master, Emory University

소외된 아프리카계 미국인 전립선암 환자의 접근을 개선하기 위한 맞춤형 생존 관리 계획을 통해 건강 지식 문제 해결

This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from where it first started (primary site) to a limited number of places in the body (oligometastatic). SCPs summarize treatment history and recommendations for monitoring and maintaining health, and may also include potential long term effects of treatments received. The intention of a SCP is to help patients participate in their own health care. However, many patients have below basic levels of health literacy, meaning, they have a lower ability to obtain, communicate, process and understand basic health information and services to make health decisions. In fact, poor health literacy has been linked with worse quality of life in prostate cancer survivors. A tailored SCP includes the addition of an educational supplement based on lower reading and writing skills (low literacy) and may address health literacy barriers to understanding of treatment options and side effects. A standard SCP uses a template based on the American Society of Clinical Oncology (ASCO) guidelines for prostate cancer. A tailored SCP with low literacy educational supplements may be more effective compared to a standard SCP in improving understanding and access to survivorship care in black or African American patients with localized or oligometastatic prostate cancer.

연구 개요

상세 설명

PRIMARY OBJECTIVES:

I. Compare outcomes after patients receive usual care from their providers with a standard SCP and after patients receive tailoring of the SCP with the low literacy educational supplement.

II. To quantify the potential benefit of tailoring the care plan and the educational supplement.

III. Compare providers' assessment of patients':

IIIa. Health literacy; IIIb. Comprehension of survivorship care recommendations; IIIc. Understanding of long term and late effects from treatment; IIId. To measures obtained from patients.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I (INTERVENTION): Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes.

GROUP II (CONTROL): Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes.

연구 유형

중재적

등록 (추정된)

150

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • 모병
        • Emory University Hospital/Winship Cancer Institute
        • 연락하다:
        • 수석 연구원:
          • Viraj Master, MD, PhD, FACS
      • Atlanta, Georgia, 미국, 30303
        • 모병
        • Grady Memorial Hospital
        • 연락하다:
        • 수석 연구원:
          • Viraj Master, MD, PhD, FACS
      • Atlanta, Georgia, 미국, 30329
        • 모병
        • Atlanta VA Medical Center
        • 연락하다:
        • 수석 연구원:
          • Mohammad Hajiha, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

남성

설명

Inclusion Criteria:

  • Black and African American men who are disease-free after completing primary surgery and/or radiation treatment for localized or oligometastatic prostate cancer between 1 to 4 years prior to enrollment. (Race/ethnicity per medical records and self report)
  • Patients who are still receiving adjuvant androgen deprivation therapy following primary radiation with non-palliative intent may be included

Exclusion Criteria:

  • Dementia or cognitive impairment per provider clinical assessment
  • Unable to give informed consent in the judgement of the patient's oncology provider
  • Recurrent prostate cancer after primary treatment
  • Less than 18 years of age at the time of informed consent
  • Diagnosis of active second malignancy requiring treatment
  • Individuals who are not able to clearly understand English since the outcome measures require understanding of English

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Group I (standard SCP, tailored SCP)

Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes.

Ancillary studies

Receive a low literacy educational supplement

다른 이름들:
  • 중재 교육
  • 교육에 의한 개입
  • 교육을 통한 개입
  • 개입, 교육

Undergo a structured interview

Receive standard SCP

다른 이름들:
  • 지지 요법
  • 증상 관리
  • 치료, 지지

Receive a tailored SCP

다른 이름들:
  • 지지 요법
  • 증상 관리
  • 치료, 지지
활성 비교기: Group II (standard SCP)

Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes.

Ancillary studies

Undergo a structured interview

Receive standard SCP

다른 이름들:
  • 지지 요법
  • 증상 관리
  • 치료, 지지

Receive a tailored SCP

다른 이름들:
  • 지지 요법
  • 증상 관리
  • 치료, 지지

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Comprehension of survivorship care recommendations and prostate specific antigen surveillance
기간: At baseline and up to 3 month phone call

Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard survivorship care plan (SCP) compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P < 0.05.

At baseline and up to 3 month phone call
Comprehension of treatment side effects and late effects
기간: At baseline and up to 3 month phone call

Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard SCP compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P < 0.05.

At baseline and up to 3 month phone call

2차 결과 측정

결과 측정
측정값 설명
기간
Access to survivorship care for late and long-term side effects
기간: At baseline and up to 3 month phone call

Will be assessed using the Patients Access Score (PAS). Descriptive statistics will be used to characterize patient access to survivorship care. The difference in mean PAS will be compared between the two arms using a 2 sample t-test. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Linear regression models will be used to identify predictors of access to survivorship care. Parsimonious models will be favored due to the relatively small sample size.

At baseline and up to 3 month phone call
Decision regret
기간: At baseline and up to 3 month phone call

Descriptive statistics will be used to characterize decision regret. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size.

At baseline and up to 3 month phone call
Change in decisional conflict
기간: At baseline and up to 3 month phone call

The two-sample t-test will be used to evaluate the change in the average decisional conflict score between patients in the control arm (standard SCP) and patients in the intervention arm (standard SCP + tailoring + educational supplement).

At baseline and up to 3 month phone call
Preparedness for survivorship
기간: At baseline and up to 3 month phone call

Descriptive statistics will be used to characterize preparedness for survivorship. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size.

At baseline and up to 3 month phone call
Patient self-efficacy
기간: At baseline and up to 3 month phone call

Descriptive statistics will be used to characterize patient self-efficacy. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size.

At baseline and up to 3 month phone call

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Viraj Master, MD, PhD, FACS, Emory University Hospital/Winship Cancer Institute

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 11월 7일

기본 완료 (추정된)

2029년 12월 31일

연구 완료 (추정된)

2030년 12월 31일

연구 등록 날짜

최초 제출

2024년 11월 4일

QC 기준을 충족하는 최초 제출

2024년 11월 4일

처음 게시됨 (실제)

2024년 11월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 30일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 29일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다